Philippe Ronchin

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.2K citations

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 716 citations · Full text

Factorial Design, Urology, × 2 +9

Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer

Emmanuel Guardiola, Frédéric Peyrade, L. Chaigneau et al. · European Journal of Cancer · 2004 · 117 citations

Neck Cancer, Oncology, Nasopharyngeal Cancer +9

Anal Canal Cancer: Management of Inguinal Nodes and Benefit of Prophylactic Inguinal Irradiation (CORS-03 Study)

Cécile Ortholan, M. Resbeut, Jean‐Michel Hannoun‐Lévi et al. · International Journal of Radiation Oncology*Biology*Physics · 2011 · 85 citations

Surgical Oncology, Cors-03 Study, Medicine +10

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Alberto Bossi, Stéphanie Foulon, Xavier Maldonado et al. · The Lancet · 2024 · 65 citations

Factorial Design, Urology, Radiation Medicine +9